Joe Regan

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.

Part of Halma Plc, LMS Medical Systems Ltd develops monitoring software for medical uses. The company is based in Montréal, Canada. The Canadian company was founded by James W. G. Turner. LMS Medical Systems was acquired by Maclos Capital, Inc. on April 01, 2004.

NATRIX Separations, Inc. manufactures and supplies single use and multi-cycle disposable chromatography products to the life science, food, beverage and water markets. Its technology consists of a polymeric hydrogel formed within a flexible porous support matrix. The firm offers NatriFlo HD-Q membrane absorbers for single-use flow-through polish applications and Natrix HD-C hydrogel membrane devices for bind-elute applications. The company was founded by Alicja Mika, Lisa Crossley, and Ronald F. Childs in 2004 and is headquartered in Burlington, Canada.

BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada.

Targeted Growth, Inc. provides biotechnological services for agricultural and energy industries. Its products include algae, canola, corn, soybean and wheat. The company was founded by Robert W. Day, James Michael Roberts, Thomas M. Todaro and Luca Comai in 1998 and is headquartered in Seattle, WA.

Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada.

Cytochroma, Inc. is a clinical-stage specialty pharmaceutical company. It develops and markets prescription products for the prevention of vitamin D insufficiency. The firm specializes in pharmaceutical products to treat and prevent secondary hyperparathyroidism associated with chronic kidney disease. The company was founded by Martin J. Petkovich in 1996 and is headquartered in Markham, Canada.

Molecular Templates, Inc. operates as a holding company that engages in the discovery and development of immunotoxins for the treatment of cancer and other serious diseases. These are capable of targeting validated therapeutic cell surface receptors but also non-traditional targets that cannot be therapeutically targeted by antibodies or small molecules. Its product pipeline consists of lead candidates for non-Hodgkin's lymphoma, multiple myeloma, and breast cancer. The company was founded by Jean Gariépy and Leigh Revers in 2009 and is headquartered in Georgetown, TX.